

Baseline systolic blood pressure and efficacy of dual antiplatelet in acute ischaemic stroke

Yu Cui 💿 , Yue Wang, Hui-Sheng Chen 💿

ABSTRACT

To cite: Cui Y, Wang Y, Chen H-S. Baseline systolic blood pressure and efficacy of dual antiplatelet in acute ischaemic stroke. *Stroke & Vascular Neurology* 2024;**0**. doi:10.1136/svn-2024-003615

Received 9 August 2024 Accepted 21 November 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Department of Neurology, General Hospital of Northern Theater Command, Shenyang, Liaoning, China

Correspondence to

Professor Hui-Sheng Chen; chszh@aliyun.com

Objective Systolic blood pressure (SBP) affects the risk of early neurological deterioration (END). This subgroup analysis of Antiplatelet Therapy in Acute Mild to Moderate Ischemic Stroke (ATAMIS) trial aimed to explore whether SBP at admission affected the efficacy of different antiplatelet therapies in preventing END.

Methods Based on the modified intention-to-treat analysis set of the ATAMIS trial, patients were divided into two subgroups according to whether SBP at admission was equal to or higher than 140 mm Hg, which were further subdivided into clopidogrel plus aspirin and aspirin alone treatments according to the randomised assignment. We conducted multivariable regression analyses to detect relationship between SBP at admission and END, as well as efficacy of different antiplatelet therapies in each SBP subgroup. Primary endpoint was END defined as ≥2-point increase in 7-day National Institutes of Health Stroke Scale score. Safety endpoints included intracranial haemorrhage and bleeding events during the trial.

Results This study included 2915 patients. Risk of END raised by 16% as SBP at admission increased by every 10 mm Hg (p<0.001). Clopidogrel plus aspirin resulted in significantly lower risk of END than aspirin alone in patients with SBP≥140 mm Hg (5.5% vs 7.9%; adjusted risk difference (RD) and 95% CI -2.5% (-4.1% to -1.0%)), but not in those with SBP<140 mm Hg (3.4% vs 4.2%; adjusted RD and 95% CI -0.8% (-3.2% to 1.7%)). Efficacy of different antiplatelet therapies and SBP did not show significant interaction (p=0.50). Safety endpoints were similar between treatments in SBP subgroups. Conclusion The risk of END increases with elevated SBP at admission among patients with acute mild-to-moderate ischaemic stroke who are not suitable for reperfusion treatments. Fewer END occurred following clopidogrel plus aspirin compared with aspirin alone across different SBP levels. The finding should be interpreted cautiously.

INTRODUCTION

Early neurological deterioration (END) was a serious complication and predicted poor functional outcomes following acute ischaemic stroke.¹ In clinical practice, it remains important to find effective treatment to reduce the risk of END. Recent three randomised clinical trials demonstrated that stronger antithrombotic strategies may be effective to prevent the occurrence of END or improve the functional outcomes following

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Systolic blood pressure (SBP) affects the risk of early neurological deterioration following stroke and the efficacy of dual antiplatelet in preventing stroke recurrence. However, no study detected the relationship between SBP and efficacy of dual antiplatelet in reducing the risk of early neurological deterioration.

WHAT THIS STUDY ADDS

⇒ In patients diagnosed with acute mild-to-moderate ischaemic stroke but not suitable for reperfusion treatment, the risk of 7-day early neurological deterioration increased with elevated SBP at admission. Different from monotherapy with aspirin alone, dual antiplatelet with clopidogrel and aspirin resulted in a decreased risk of early neurological deterioration regardless of patients' SBP at admission.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ These findings support the use of dual antiplatelet with clopidogrel and aspirin for preventing the occurrence of early neurological deterioration in acute mild-to-moderate ischaemic stroke regardless of SBP at admission. This should be interpreted cautiously.

END in acute ischaemic stroke.^{2–4} History of hypertension, higher blood pressure parameters at admission and blood pressure variability at acute phase were found to predict the occurrence of END.^{5–7} Chronic hypertension reduced the ability of collateral development by impairing microvascular function and change in blood pressure reduced cerebral haemodynamic reserve,⁸ which contributed to the development of END. Whether the blood pressure in acute phase will affect the efficacy of antithrombotic strategies is worth exploring.

Previous studies detected the relationship between baseline systolic blood pressure (SBP) level and the choice of initial antiplatelet therapy⁹ or efficacy of dual antiplatelet in preventing stroke recurrence.¹⁰ However, few studies investigate the relationship between baseline SBP levels and efficacy of dual antiplatelet therapy in preventing the





1

occurrence of END. Dual antiplatelet therapy reduced the occurrence of END based on its strong antithrombotic efficacy, which may result in improving cerebral blood flow supply.¹¹ Given that change in blood pressure reflected poor function in cerebral autoregulation caused by direct damage to the modulatory centres in acute ischaemic stroke (eg, an overall impaired autoregulation when cerebral perfusion pressure increased 30%),^{12 13} which was associated with neurological deterioration after stroke by affecting cerebral blood flow supply and perfusion pressure,^{14 15} the level of SBP at admission may be associated with the efficacy of dual antiplatelet in preventing the occurrence of END.

According to the Antiplatelet Therapy in Acute Mild to Moderate Ischemic Stroke (ATAMIS) trial, dual antiplatelet therapy with clopidogrel and aspirin, compared with aspirin alone, significantly prevented END at 7 days in patients diagnosed with acute mild-to-moderate ischaemic stroke who were not suitable for reperfusion treatments.⁴ Based on the above discussion, we performed a subgroup analysis of ATAMIS to determine the association of SBP at admission with efficacy of different antiplatelet therapies in this population.

METHODS

Study design and population

Previous studies reported the details of ATAMIS trial,^{4 16} which was a randomised clinical trial designed with multicentre, open-label and blinded-endpoint, enrolling 3005 patients between 20 December 2016 and 9 August 2022, and finishing in October 2022. The trial aimed to compare the efficacy in preventing the occurrence of END between clopidogrel plus aspirin and aspirin alone in the target population, who were administrated within 48 hours of symptom onset and diagnosed with acute ischaemic stroke presenting 4-10 points on the National Institutes of Health Stroke Scale (NIHSS) score at admission. Patients were excluded if they received any reperfusion treatment, were treated with anticoagulation drugs, experienced intracerebral haemorrhage, urinary tract bleeding or gastrointestinal bleeding, received carotid revascularisation and were allergic to study drugs. Detailed information about the screening criteria and defining analysis set were shown in the previous report.⁴ The modified intention-to-treat analysis was conducted as the primary analysis strategy in the ATAMIS trial, from which all the patients were included in the current study. The current study was in accordance with the principle of the Consolidated Standards of Reporting Trials.

Patient and public involvement

No patients were involved.

Procedures

In the ATAMIS, patients enrolled were randomly assigned to receive clopidogrel plus aspirin (day 1: 300 mg clopidogrel and 100 mg aspirin; days 2–14: 75 mg clopidogrel and 100 mg aspirin) or aspirin alone (days 1–14: Stroke Vasc Neurol: first published as 10.1136/svn-2024-003615 on 8 December 2024. Downloaded from http://svn.bmj.com/ on May 4, 2025 by guest. Protected by copyright

100–300 mg aspirin).⁴ In this analysis, included patients were first divided into two subgroups: SBP≥140mm Hg and SBP<140mm Hg based on the results from our previous study, which indicated that dual antiplatelet therapy significantly reduced the occurrence of END in patients with minor stroke and presenting ≥140 mm Hg at admission.¹⁷ The baseline SBP was measured at admission. In the ATAMIS trial, if the SBP≥200 mm Hg or diastolic blood pressure (DBP) ≥110mm Hg, patients were treated with antihypertensive treatment to control blood pressure according to the current guideline in China. In the visits of admission, day 7 and day 14 after randomisation, NIHSS score was measured to evaluate the neurological status. In the follow-up visit of day 90 after randomisation, modified Rankin Scale (mRS) score, bleeding or ischaemic vascular events were collected.

Outcomes

In the current study, all the endpoints were kept consistent with the ATAMIS.⁴ The primary endpoint was END, defined as \geq a 2-point increase in 7-day NIHSS score compared with admission (excluding due to cerebral haemorrhage).¹⁸ The secondary endpoints included excellent functional outcome (mRS scoring 0–1 at 90 days); shift distribution of ordinal mRS scores at 90 days; change in 14-day NIHSS scores compared with admission; time from randomisation to the occurrence of new stroke¹⁹; and time from randomisation to the occurrence of other vascular events or all-cause mortality. The safety endpoints were set as any bleeding events and intracranial haemorrhage which may result from antiplatelet treatments.

Statistical analysis

Adjusted analysis was defined as the primary analysis to remove the potential imbalanced bias from characteristics between treatment groups in post hoc analysis. We summarised categorical variables as frequencies with percentages and continuous variables as median with IQR for the baseline characteristics, which were compared by χ^2 test and Mann-Whiney U test. We calculated the absolute number of events for the endpoints, and estimated the treatment effects with 95% CIs using risk difference (RD) for END, excellent functional outcome and safety endpoints, OR for ordinal mRS scores, geometric mean ratio for change in NIHSS scores or HR for timedependent endpoints, which were parallel with the ATAMIS trial.⁴

First, as a continuous variable, binary logistic regression analysis was performed to explore the association of END with SBP at admission. Multivariable logistic regression model was performed to calculate probability score by including covariates such as antiplatelet therapy, age, sex, diabetes mellitus, history of hypertension, time from stroke onset to antiplatelet therapy, NIHSS score at randomisation and presumed stroke cause,²⁰ which were prespecified in the ATAMIS trial.⁴

Second, efficacies of different antiplatelet therapies were investigated by adjusted and unadjusted generalised linear models or Cox regression models in dichotomous SBP subgroups. Unbalanced baseline variables compared between treatment groups with p<0.1 were included in the adjusted model. Interactions between SBP and efficacy of antiplatelet therapy were conducted by adjusting unbalanced baseline variables between SBP subgroups.

Third, considering the unbalanced sample size between SBP subgroups, we performed propensity score matching analysis to address the bias. Baseline variables with p<0.1 between subgroups and treatments were matched by the nearest method, 1:1 of ratio and 0.05 of calliper value. The risk of END between treatments will be compared in each SBP subgroup of the new analysis set.

Exploratory analyses were performed in the current study and evaluated the nominal p value that would be statistically significant if it was less than 0.05. Analyses were conducted by SPSS software (V.26.0) and figures were prepared by R software (V.4.1.3, R Foundation for Statistical Computing).

RESULTS Patient characteristics

Overall, 2915 patients were included in the current study including 1502 patients assigned to clopidogrel plus aspirin (454 patients with SBP<140 mm Hg and 959 patients with SBP≥140 mm Hg) and 1413 patients assigned to aspirin alone (496 patients with SBP<140 mm Hg and 1006 patients with SBP≥140 mm Hg). The flow diagram of patient screening is shown in figure 1.

In patients with SBP<140 mm Hg, there was not any significant imbalance of baseline characteristics between antiplatelet treatments. In patients with SBP≥140 mm Hg, there were some imbalances in diabetes mellitus, location of responsible vessel and DBP at admission between treatment groups. Between patients with SBP<140 mm Hg and those with SBP≥140 mm Hg, there were some imbalances in sex, history of hypertension, previous stroke, blood pressures at admission, blood glucose at admission, NIHSS score at admission, time from stroke onset to antiplatelet therapy and previous hypertension



Figure 1 Trial profile. SBP, systolic blood pressure.

3

treatment. Further information about baseline characteristics between SBP subgroups or antiplatelet treatments is shown in table 1.

Association between baseline SBP and END

We investigated the relationship between continuous SBP at admission and risk of END. The risk of END was raised as the SBP at admission increased (figure 2A), which was also, respectively, detected in patients treated with different antiplatelet treatments (figure 2B). The risk of END increased as the SBP at admission increased in both the two treatment groups, kept higher in the aspirin alone group and the gap of risk between treatment groups seemed consistent as the SBP at admission increased. In the multivariable logistic regression analysis, the likelihood of END at 7 days was associated with SBP at admission (adjusted OR 1.16; 95% CI 1.08 to 1.24; p<0.001; figure 2), which indicated that the risk of END increased.

Association between baseline SBP and efficacy of antiplatelet therapy

In table 2, the results showed clopidogrel plus aspirin significantly decreased risk of END compared with aspirin alone in patients with SBP>140 mm Hg (5.5% vs 7.9%; adjusted RD and 95% CI –2.5% (–4.1% to –1.0%), p<0.01) but did not show a significant difference in the patients with SBP<140 mm Hg (3.4% vs 4.2%; adjusted RD and 95% CI –0.8% (–3.2% to 1.7%), p=0.54). Efficacy of different antiplatelet therapies and SBP did not show significant interaction (adjusted p=0.50). In the propensity score matching analysis, clopidogrel plus aspirin also resulted in fewer END than aspirin alone in each SBP subgroup. However, the difference between treatments in the SBP>140 mm Hg subgroup lost statistical significance (table 3).

The 90-day mRS score distribution between antiplatelet treatments in SBP subgroups is shown in figure 3. The proportion of mRS scoring 0-1 between the two treatment groups was similar in the patients with SBP<140 mm (80.8% vs 78.5%; adjusted RD and 95% CI 2.3% (-2.9% to 7.5%), p=0.38) and the patients with SBP \geq 140 mm Hg (74.9% vs 72.7%; adjusted RD and 95% CI 2.2% (-0.6% to 5.0%), p=0.12). Furthermore, the ordinal regression analysis showed that the distribution of mRS score was also similar between two antiplatelet treatments in the patients with SBP<140mm Hg (adjusted OR and 95% CI 1.07 (0.84 to 1.36), p=0.59) and the patients with SBP≥140 mm Hg (adjusted OR and 95% CI 1.09 (0.97 to 1.23), p=0.14). All the other secondary endpoints and safety endpoints were not significantly different between treatments in any subgroup, and no interactions were found (table 2).

DISCUSSION

In this ATAMIS post hoc analysis, we found that the risk of END increased as the SBP at admission increased in patients receiving dual-antiplatelet and mono-antiplatelet treatments. As we divided patients into SBP subgroups using 140 mmHg as a cut-off, we found that clopidogrel plus aspirin resulted in fewer END compared with aspirin alone in those with baseline SBP≥140 mmHg. However, the difference lost significance after balancing sample size between SBP subgroups.

END was previously reported to be a serious and frequent complication following stroke.²¹ Although blood pressure is an important clinical characteristic of patients diagnosed with ischaemic stroke and contributes to patients' prognosis,²²⁻²⁴ the association between baseline SBP levels and END remains unclear.⁵ In the current study, we found that the risk of END raised with elevated SBP level at admission, which was similar to those reported in retrospective observational studies from China.²⁵ It has previously been reported that higher SBP at admission reflected poor cerebral autoregulation,²⁶ which was associated with poor prognosis after stroke by leading to great blood pressure variability.⁷ We found that the association of SBP at admission with END was consistent among patients treated with either dual antiplatelet therapy or antiplatelet monotherapy. However, in the current study, patients with SBP≥140 mm Hg at admission benefited more from dual antiplatelet therapy than antiplatelet monotherapy with respect to the occurrence of END. Increase in SBP following stroke might reflect the impairment of cerebral autoregulation function caused by direct damage to the modulatory centres after stroke, which was common in acute ischaemic stroke.¹²¹³ Cerebral autoregulation maintained cerebral blood flow supply and perfusion pressure that was associated with stroke progression.¹⁴ ¹⁵ Dual antiplatelet therapy with stronger antithrombotic effect contributed to preventing reocclusion of the responsible blood vessel, which would improve the poor cerebral blood flow supply caused by the impaired cerebral autoregulation.²⁷ Additionally, increased cerebral blood flow was previously reported to result in improving neurological function.²⁸ Thus, the effect of dual-antiplatelet versus mono-antiplatelet therapy on preventing END and improving neurological function among patients with SBP≥140 mm Hg may result from stronger antithrombotic effects of dual antiplatelet therapy, which may result in improvements in cerebral blood flow in the context of elevated blood pressure. Given that the significant difference in END between treatments disappeared after reducing sample size of patients with SBP≥140 mm Hg, the potential benefit in this population warrants further investigation. In addition, previous studies mainly investigated the association between blood pressure at admission and END with early time window from 24 to 72 hours.^{17 29} Considering that more confounders may affect the neurological deterioration with the time window expanding,³⁰ the association may be weakened. Thus, the inference needs further validation by measuring cerebral blood flow and perfusion in the early stage following stroke and adopting END defined within shorter time window after stroke onset.

Total r Age, years 65 (58) Age, years 65 (58) Sex 65 (67) Sex 65 (76) Male 657 (61) Male 657 (61) Permale 293 (31) Current smoking 325/94 Current smoking 325/94 Current drinking* 190/94 Hypertension 448 (41) Diabetes mellitus 238 (21) Previous stroke‡ 327/94	patients 0) 93.2) 93.2) 42.34.5) 41.(20.2) 41.(20.2) 41.(20.2) 41.2)	Clopidogrel plus aspirin (N=496)	Aspirin alone				Acnirin alone		
Age, years 65 (58) Sex 657 (6) Male 657 (6) Permale 293 (3) Current smoking 325/94 Current drinking* 190/94 Hypertension 448 (4) Diabetes mellitus 238 (2) Previous stroke‡ 327/94	73) 19.2) 18.6) 42.(34.5) 41.(20.2) 41.(20.2) 41.2)		(N=454)	P value	Total patients (N=1965)	Clopidogrel plus aspirin (N=1006)	(N=959)	P value	P value§§
Sex Male 657 (6) Female 293 (3) Current smoking 325/94 Current drinking* 190/94 Comorbidities† 190/94 Comorbidities† 190/94 Comorbidities† 238 (2) Diabetes mellitus 238 (2) Previous stroke‡ 327/94	19.2) 10.8) 42 (34.5) 41 (20.2) 41 (20.2)	66 (58–73)	65 (59–73)	0.46	66 (59–74)	66 (59–73)	66 (59–74)	0.11	0.27
Male657 (6)Female523 (3)Current smoking225/93Current drinking*190/93Comorbidities†190/94Hypertension448 (4)Diabetes mellitus238 (2)Previous stroke‡327/94	.9.2) (0.8) 42 (34.5) 41 (20.2) 41 (20.2) 47.2)								
Female293 (3)Current smoking325/94Current drinking*190/94Comorbiditiest190/94Hypertension448 (4)Diabetes mellitus238 (2)Previous stroke‡327/94	0.8) 42 (34.5) 41 (20.2) 47.2) 55.1)	344 (69.3)	313 (68.9)	0.89	1238 (63.0)	628 (62.4)	610 (63.6)	0.59	<0.01
Durrent smoking325/94Durrent drinking*190/94Comorbidities†190/94Hypertension448 (4Diabetes mellitus238 (2)Previous stroke‡327/94	42 (34.5) 41 (20.2) 47.2) 25.1)	152 (30.6)	141 (31.1)		727 (37.0)	378 (37.6)	349 (36.4)		
Durrent drinking* 190/94 Comorbidities† 148 (4 Hypertension 448 (2) Diabetes mellitus 238 (2) Previous stroke‡ 327/94	41 (20.2) 47.2) 25.1)	165/491 (33.6)	160/451 (35.5)	0.55	642/1950 (32.9)	338/998 (33.9)	304/952 (31.9)	0.36	0.40
Comorbidities† Hypertension 448 (4: Diabetes mellitus 238 (2: Previous stroke‡ 327/94	17.2) 25.1)	104/491 (21.2)	86/450 (19.1)	0.43	400/1950 (20.5)	197/998 (19.7)	203/952 (21.3)	0.39	0.84
Hypertension 448 (4: Diabetes mellitus 238 (2: Previous stroke‡ 327/94	(7.2) 25.1)								
Diabetes mellitus 238 (2) Previous stroke‡ 327/94	25.1)	229 (46.2)	219 (48.2)	0.52	1362 (69.3)	702 (69.8)	660 (68.8)	0.65	<0.01
Previous stroke‡ 327/9/		115 (23.2)	123 (27.1)	0.17	504 (25.6)	286 (28.4)	218 (22.7)	<0.01	0.73
	42 (34.7)	176/490 (35.9)	151/452 (33.4)	0.42	612/1958 (31.3)	306/1001 (30.6)	306/957 (32.0)	0.50	0.06
Previous transient 5/943 ischaemic attack	(0.5)	3/493 (0.6)	2/450 (0.4)	0.73	7/1951 (0.4)	4/1000 (0.4)	3/951 (0.3)	0.76	0.50
Blood pressure at randomisatio	on, mm Hg								
Systolic 132 (1)	26-140)	133 (127–140)	131 (125–140)	0.18	160 (151–176)	160 (151–177)	160 (151–176)	0.10	<0.01
Diastolic 80 (78-	(06-1	80 (77–90)	80 (79–90)	0.97	90 (86–100)	92 (86–100)	90 (85–100)	0.08	<0.01
Blood glucose, mmol/L 5.9 (5.	.1–7.7)	5.9 (5.1–7.5)	5.9 (5.1–8.1)	0.89	6.1 (5.3–8.1)	6.2 (5.3–8.1)	6.1 (5.2–7.9)	0.41	<0.01
Baseline NIHSS score§ 4 (4-6)		4 (4-6)	5 (4-6)	0.80	5 (4-6)	5 (4-6)	5 (4-6)	0.87	0.04
Estimated premorbid function (i	(mRS)¶								
No symptoms 658 (6)	19.3)	334 (67.3)	324 (71.4)	0.40	1414 (72.0)	722 (71.8)	692 (72.2)	0.38	0.26
Symptoms without 290 (3) disability	30.5)	161 (32.5)	129 (28.4)		549 (27.9)	282 (28.0)	267 (27.8)		
Mild disability 2 (0.2)		1 (0.2)	1 (0.2)		2 (0.1)	2 (0.2)	0 (0.0)		
Time from stroke onset 19.1 (8 to antiplatelet therapy, nours	8.2–26.0)	18.6 (8.1–26.0)	19.5 (8.3–26.1)	0.75	16.8 (7.4–26.1)	16.8 (7.1–26.0)	16.9 (7.8–26.3)	0.91	0.06
Presumed stroke cause**									
Undetermined cause 600/94	49 (63.2)	306/495 (61.8)	294 (64.8)	0.44	1172/1961 (59.8)	611/1004 (60.9)	561/957 (58.6)	0.28	0.18
Small artery 286/9₄ occlusion	49 (30.1)	160/495 (32.3)	126 (27.8)		612/1961 (31.2)	294/1004 (29.3)	318/957 (33.2)		
Large artery 28/945 atherosclerosis	9 (6.3)	28/495 (5.7)	32 (7.0)		165/1961 (8.4)	91/1004 (9.1)	74/957 (7.7)		
Other determined 2/949 cause	(0.2)	1/495 (0.2)	1 (0.2)		9/1961 (0.5)	6/1004 (0.6)	3/957 (0.3)		
Cardioembolic 1/949	(0.1)	0/495 (0.0)	1 (0.2)		3/1961 (0.2)	2/1004 (0.2)	1/957 (0.1)		

5

Stroke Vasc Neurol: first published as 10.1136/svn-2024-003615 on 8 December 2024. Downloaded from http://svn.bmj.com/ on May 4, 2025 by guest. Protected by copyright.

6

õ

rok
e <
asc
Net
urol
firs
stp
Jbli
she
das
10
36/s
ŝŸņ-
202
4-0
036
515
on
0 0 0
ece
mbe
9r 2
024
D
nwc
load
ded
fror
n n
ttp:/
/svr
ו.bn
nj.co
)m
on
May
,4 ,
202
.5 5
y gi
Jest
:⁺ ₽
_
rote
rotecte
rotected by
rotected by co
rotected by copyrig

Table 1 Continue	Q								
	SBP<140mm Hg				SBP≥140mm Hg				
	Total patients (N=950)	Clopidogrel plus aspirin (N=496)	Aspirin alone (N=454)	P value	Total patients (N=1965)	Clopidogrel plus aspirin (N=1006)	Aspirin alone (N=959)	P value	P value§§
Anterior	571/794 (71.9)	303/425 (71.3)	268/369 (72.6)	0.88	1209/1713 (70.6)	607/892 (68.0)	602/821 (73.3)	<0.01	0.38
Posterior	195/794 (24.6)	106/425 (24.9)	89/369 (2.1)		456/1713 (26.6)	265/892 (29.7)	191/821 (23.3)		
Anterior and posterior	16/794 (3.8)	16/425 (3.8)	12/369 (3.3)		48/1713 (2.8)	20/892 (2.2)	28/821 (3.4)		
Patients receiving hypertension treatment[]	107 (11.3)	62 (12.5)	45 (9.9)	0.21	541 (27.5)	280 (27.8)	261 (27.2)	0.76	<0.01
Timing of starting treatment after admission, days	0 (0-4)	0 (0-4)	0 (0-4)	0.48	0 (0–2)	0 (0-2)	0 (0–2)	0.52	0.73
Patients receiving hyperglycaemia treatment‡‡	93 (9.8)	45 (9.1)	4 (10.6)	0.44	223 (11.3)	121 (12.0)	102 (10.6)	0.33	0.20
Timing of starting treatment after admission, days	0 (0–1)	0 (0-1)	0 (0–1)	0.50	0 (0–1)	0 (0-1)	0 (0–2)	0.47	0.43
The data were shown wi *Current drinker means o †The comorbidities were ±Previous ischaemic strot	th median (IQR) for contir consuming alcohol at leas based on the patient or 1 ske referred only to the pa	ruous characteristic or freq st once a week within 1 yes family report. atients with prestroke mRS	luency (percentages) for ar before onset of the dis <1.	categorical ch ease and cons	aracteristic. uming alcohol continuously	for more than 1 year.			

**The presumed stroke cause was classified according to the Trial of Org 10.172 in Acute Stroke Treatment classification system²⁰ using clinical findings, brain imaging and laboratory tests. Other determined causes Provide the management of the second of the second scores range from 0 to 42, with higher scores indicating more severe neurological deficit. Second severe neurological deficit. If Scores on the mRS of functional disability range from 0 (no symptoms) to 6 (death). No symptoms indicates scoring 0, symptoms without disability indicates scoring 2.

included pulmonary embolism, peripheral vessel incident and cardiovascular incident.

1+Type of antihypertension drug included ACE inhibitors and angiotensin receptor blocker (106/648), beta receptor blocker (15/648), calcium channel blocker (479/648), diuretic (5/648) and others (43/648).

t‡The population included 742 patients who were diagnosed with diabetes mellitus and 130 patients who were found hyperglycaemia at admission. §§The p value represented the significance when compared between SBP<140 mm Hg and SBP≥140 mm Hg subgroups.

mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure.



Figure 2 Association of baseline SBP with risk of END. (A) The probability score of END at 7 days raised with SBP at admission increasing. (B) The probability score of END was stratified by treatment groups, raised as the SBP at admission increased in both two treatment groups and kept higher in the aspirin alone group, and the gap of probability score between treatment groups seemed to be consistent. The baseline SBP was associated with the risk of END (adjusted OR, 1.16; 95% Cl, 1.08 to 1.24; p<0.001). END, early neurological deterioration; SBP, systolic blood pressure.

For the secondary outcomes, compared with aspirin alone, dual antiplatelet therapy with clopidogrel plus aspirin did not show a significant difference with respect to long-term functional outcomes such as mRS scoring 0 to 1 and distribution of mRS score at 90 days, which was similar to that from the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) study.³¹ We inferred that this result may result from the mild neurological deficits of the population (median NIHSS scoring 4–5 at admission). In addition, lack of statistical power due to the original design of ATAMIS trial for preventing END and small sample size after dividing into SBP subgroups resulted in the similar occurrence of new stroke or other vascular events within 90 days between treatment groups. We admitted several limitations in the current study.

First, although a relatively large population with 950 and

1965 patients were, respectively, included in each SBP

subgroup in the study, an unbalanced sample size may

introduce bias. The propensity score matching anal-

ysis potentially addressed the selection and unbalanced

bias. Second, due to the lack of blood pressure recorded

\cap	
6	
U	

	Subgroup	Clopidogrel plus aspirin (N=1502)	Aspirin alone (N=1413)	Treatment effect metric	Unadjusted Treatment difference (95% CI)	P value	Adjusted Treatment difference (95% CI)	P value	P _{int} value
Primary outcome									
END at 7 days*	SBP<140mm Hg	17/496 (3.4)	19/454 (4.2)	RD†	-0.8 (-3.2 to 1.7)	0.54	-0.8 (-3.2 to 1.7)	0.54	0.50
	SBP≥140mm Hg	55/1006 (5.5)	76/959 (7.9)		-2.5 (-4.7 to -0.2)	0.03	-2.5 (-4.1 to -1.0)	<0.01	
Secondary outcomes									
mRS 0-1 at 90days‡	SBP<140mm Hg	395/489 (80.8)	346/441 (78.5)	RD†	2.3 (-2.9 to 7.5)	0.38	2.3 (-2.9 to 7.5)	0.38	06.0
	SBP≥140mm Hg	735/981 (74.9)	669/920 (72.7)		2.2 (-1.7 to 6.2)	0.27	2.2 (-0.6 to 5.0)	0.12	
mRS at 90 days‡	SBP<140mm Hg	NA	NA	OR§	1.07 (0.84 to 1.36)	0.59	1.07 (0.84 to 1.36)	0.59	0.96
	SBP≥140mm Hg	NA	NA		1.10 (0.93 to 1.29)	0.28	1.09 (0.97 to 1.23)	0.14	
Change in NIHSS at 14 day¶	SBP<140mm Hg	-0.69 (-1.25 to -0.34)	-0.65 (-1.61 to -0.34)	GMR†	0.02 (-0.57 to 0.59)	0.96	-0.15 (-0.72 to 0.42)	0.60	0.98
	SBP≥140mm Hg	-0.51 (-0.92 to -0.22)	-0.51 (-0.92 to -0.22)		0.32 (-0.28 to 0.91)	0.29	0.32 (-0.09 to 0.73)	0.13	
New stroke within 90 days**	SBP<140mmHg	3/489 (0.6)	3/441 (0.7)	HR††	0.90 (0.18 to 4.47)	06.0	0.90 (0.18 to 4.47)	06.0	0.74
	SBP≥140mm Hg	9/981 (0.9)	10/920 (1.1)		0.85 (0.34 to 2.08)	0.71	0.82 (0.33 to 2.04)	0.65	
Other vascular events or death	SBP<140mm Hg	6/489 (1.2)	2/441 (0.5)	HR††	2.72 (0.55 to 13.47)	0.22	2.72 (0.55 to 13.47)	0.22	0.39
within 90 days	SBP≥140mm Hg	10/981 (1.0)	10/920 (1.1)		0.94 (0.39 to 2.25)	0.89	0.93 (0.39 to 2.24)	0.87	
Safety outcomes									
Any bleeding events	SBP<140mm Hg	6/496 (1.2)	5/454 (1.1)	RD†	0.1 (-1.3 to 1.5)	0.88	0.1 (-1.3 to 1.5)	0.88	0.65
	SBP≥140mm Hg	4/1006 (0.4)	9/959 (0.9)		-0.5 (-1.3 to 0.2)	0.14	-0.5 (-1.1 to 0.0)	0.05	
Intracranial haemorrhage	SBP<140mm Hg	1/496 (0.2)	1/454 (0.2)	RD†	0.0 (-0.6 to 0.6)	0.95	0.0 (-0.6 to 0.6)	0.95	0.99
	SBP≥140mm Hg	0/1006 (0.0)	1/959 (0.1)		-0.1 (-0.3 to 0.1)	0.31	-0.1	0.14	
The data were shown with median (I. "END was defined as an increase bet "END was defined as an increase bet tCalculated using the generalised lin ‡scores on the mRS of function al of \$A shift measures of function accordia ¶Patients with NIHSS scores of 4–10 "New stroke included ischaemic stro #TO alculated using the Cox regressic END, early neurological deterioration;	AP) for continuous characteris ween baseline and 7 days of 2 ability range from 0 (no sympt ability range of scores, were eligible for this study; N we and haemorrhagic stroke. on model.	stic or frequency (percentages) for ci 22 on the NIHSS score, but not as re toms) to 6 (death). on the mRS at 90 days was analyse IIHSS scores range from 0 to 42, wit mRS, modified Rankin Scale; NA, n	ategorical characteristic. ssult of cerebral haemornhag d by ordinal logistic regress h higher scores indicating n ot applicable; NIHSS, Natio	ge. ¹⁸ je. nore severe neurolo nal Institute of Heal	gical deficit. The log (NIHSS th Stroke Scale; RD, risk dif	5+1) was analy ference; SBP, s	sed using generalised linear n ystolic blood pressure.	. Iodel.	

Table 3 Propensi	ty score matching analysis	for primary outcome				
Primary outcome	Subgroup	Clopidogrel plus aspirin	Aspirin alone	RD (95% CI)*	P value	P _{int} value
END at 7 days†	SBP<140 mm Hg (N=940)	17/490 (3.5)	19/450 (4.2)	-0.8 (-3.2 to 1.7)	0.55	0.91
	SBP≥140 mm Hg (N=940)	27/494 (5.5)	31/446 (7.0)	-1.5 (-4.6 to 1.6)	0.35	

*Calculated using the generalised liner model.

†END was defined as an increase between baseline and 7 days of ≥ 2 on the NIHSS score, but not as result of cerebral haemorrhage.¹⁸

END, early neurological deterioration; NIHSS, National Institutes of Health Stroke Scale; RD, risk difference; SBP, systolic blood pressure.

index ischaemic stroke was not available. Third, the findings lacked some examination of cerebral autoregulation such as cerebral blood flow or perfusion in the acute phase following stroke, which might support the inference about the association between baseline SBP and efficacy of dual antiplatelet therapy on improving neurological function. Fourth, as the ATAMIS did not include patients eligible for reperfusion treatments, as well as those with cardioembolic stroke, our findings are not generalisable to the above population. Fifth, a cohort with non-Chinese population would be needed to validate the generalisability. Finally, as the exploration characteristic of post hoc analysis, we cautiously interpreted our findings.

In conclusion, this ATAMIS subgroup analysis suggests that among patients who were diagnosed with acute mild-to-moderate ischaemic stroke and not suitable



Figure 3 Distribution of modified Rankin Scale Score at 90 days. The raw distribution of scores was shown in two treatment groups of all the patients (A), the patients with SBP>140 mm Hg (B), and the patients with SBP<140 mm Hg (C). Scores ranged from 0 to 6. 0=no symptoms, 1=symptoms without clinically significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability and 6=death. SBP, systolic blood pressure.

for reperfusion treatments, the risk of END raised with elevated SBP at admission, and clopidogrel plus aspirin treatment may produce benefit across SBP levels with respect to preventing 7-day END. This finding should be cautiously interpreted and needs to be confirmed in the future.

Contributors H-SC contributed to conception and design of the study; YC contributed to analysis of data and drafting the original manuscript; YW contributed to acquisition of data. H-SC is the guarantor.

Funding This study was funded by Science and Technology Project Plan of Liaoning Province (2019JH2/10300027).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and all study procedures were reviewed and approved by the Ethics Committee of General Hospital of Northern Theater Command (Approval Number: k (2016) 6-1). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Yu Cui http://orcid.org/0000-0002-4925-1500 Hui-Sheng Chen http://orcid.org/0000-0002-7486-1992

REFERENCES

- Seners P, Turc G, Oppenheim C, et al. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry 2015;86:87–94.
- 2 Zhao W, Li S, Li C, et al. Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol 2024;81:594–602.
- 3 Zhang X, Zhong W, Xue R, *et al.* Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomized Clinical Trial. *JAMA Neurol* 2024;81:118–25.
- 4 Chen H-S, Cui Y, Wang X-H, et al. Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial. JAMA Neurol 2024;81:450–60.
- 5 Cui Y, Meng WH, Chen HS. Early neurological deterioration after intravenous thrombolysis of anterior vs posterior circulation stroke: a secondary analysis of INTRECIS. *Sci Rep* 2022;12:3163.
- 6 Geeganage C, Tracy M, England T, *et al.* Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). *Stroke* 2011;42:491–3.
- 7 Chung J-W, Kim N, Kang J, et al. Blood pressure variability and the development of early neurological deterioration following acute ischemic stroke. J Hypertens 2015;33:2099–106.
- 8 Thanvi B, Treadwell S, Robinson T. Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management. *Postgrad Med J* 2008;84:412–7.
- 9 Liu T, Wang Y, Niu X, et al. Evaluation of the association between admission systolic blood pressure and the choice of initial antiplatelet

therapy for minor ischemic stroke in real-world. *J Clin Hypertens* (Greenwich) 2022;24:465–74.

- 10 de Havenon A, Johnston SC, Easton JD, et al. Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial. *JAMA Netw Open* 2021;4:e2112551.
- 11 Feng Q, Yue W, Hui C, et al. Effects of combined antiplatelet treatment on cerebral hemodynamics and platelet parameters in progressive stroke patients. J Med Postgra (Chinese) 2017;30:1065–70.
- 12 Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke. Stroke 2009;40:2251–6.
- 13 Aries MJH, Elting JW, De Keyser J, *et al.* Cerebral autoregulation in stroke: a review of transcranial Doppler studies. *Stroke* 2010;41:2697–704.
- 14 Jordan JD, Powers WJ. Cerebral autoregulation and acute ischemic stroke. Am J Hypertens 2012;25:946–50.
- 15 Alawneh JA, Moustafa RR, Baron JC. Hemodynamic factors and perfusion abnormalities in early neurological deterioration. *Stroke* 2009;40:e443–50.
- 16 Hou X, Li X, Wang X, et al. Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a parallel, randomised, open-label, multicentre, prospective study. Stroke Vasc Neurol 2018;3:263–7.
- 17 Cui Ý, Zhao Z-A, Wang J-Q, et al. Systolic blood pressure and early neurological deterioration in minor stroke: A post hoc analysis of ARAMIS trial. CNS Neurosci Ther 2024;30:e14868.
- 18 Yi X, Zhou Q, Wang C, et al. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. J Neurol 2018;265:2396–403.
- 19 Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:2064–89.
- 20 Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1999;24:35–41.
- 21 Liu H, Liu K, Zhang K, et al. Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study. Ther Adv Neurol Disord 2023;16:17562864221147743.
- 22 Bangalore S, Schwamm L, Smith EE, et al. Blood pressure and inhospital outcomes in patients presenting with ischaemic stroke. Eur Heart J 2017;38:2827–35.
- 23 Luo T, Cui JS, Peng H, et al. Effect of blood pressure on the prognosis of acute ischemic stroke patients caused by anterior circulation large vessel occlusion without recanalization. *Clin Neurol Neurosurg* 2023;224:107540.
- 24 Katsanos AH, Joundi RA, Palaiodimou L, et al. Blood Pressure Trajectories and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke. *Hypertension* 2024;81:629–35.
- 25 Zhang Y-B, Su Y-Y, He Y-B, et al. Early Neurological Deterioration after Recanalization Treatment in Patients with Acute Ischemic Stroke: A Retrospective Study. *Chin Med J (Engl)* 2018;131:137–43.
- 26 McManus M, Liebeskind DS. Blood Pressure in Acute Ischemic Stroke. J Clin Neurol 2016;12:137–46.
- 27 Feler J, Chuck C, Anderson M, et al. Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion. *Interv Neuroradiol* 2023;29:540–7.
- 28 Zhao Z-A, Zhang N-N, Tao L, et al. Effect of head-down tilt on clinical outcome and cerebral perfusion in ischemic stroke patients: A case series. Front Neurol 2022;13:992885.
- 29 Tan C, Zhao L, Dai C, et al. Risk factors related to early neurological deterioration in lacunar stroke and its influence on functional outcome. Int J Stroke 2023;18:681–8.
- 30 Erdur H, Scheitz JF, Ebinger M, et al. In-hospital stroke recurrence and stroke after transient ischemic attack: frequency and risk factors. Stroke 2015;46:1031–7.
- 31 Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9.